Children With Inflammatory Bowel Diseases are Disadvantaged by Current Drug Approval Policies: A Call for Urgent Change
Authors:
Open Access
- 10 April 2025
- journal article
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 7 (2) , otaf036
Abstract
Treatment of pediatric inflammatory bowel disease (IBD) is significantly hindered by the lack of US Food and Drug Administration-approved biologic and small-molecule medications. This review explains the burdens faced by children with IBD because of this problem and appraises the marked historical timeline differences in medication approval between adults and children with IBD. The authors follow with an in-depth focus on the pointed disparity in approved therapies for children with IBD compared to children with rheumatologic immune-mediated diseases, highlighting the differences in stringency of evidence that has been used to gain medication approval for children with rheumatologic diseases. The editorial concludes with a call for change in regulatory agency protocols, to adopt a modernized strategy that will expedite the approval of advanced therapies for children with IBD.Keywords
This publication has 14 references indexed in Scilit:
- An Open Letter to the Food and Drug Administration and Pharmaceutical Industry Concerning Drug Approval for Children With Inflammatory Bowel DiseaseInflammatory Bowel Diseases, 2024
- Prior Authorizations Delay Therapy, Impact Decision-making, and Lead to Adverse Events in Inflammatory Bowel Disease: 2022 Provider SurveyClinical Gastroenterology and Hepatology, 2023
- Paediatric Inflammatory Bowel Disease: A Multi-Stakeholder Perspective to Improve Development of Drugs for Children and AdolescentsJournal of Crohn's and Colitis, 2022
- Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 studyThe Lancet Gastroenterology & Hepatology, 2021
- Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritisRheumatology, 2021
- Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritisRheumatology, 2021
- Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2)Annals of the Rheumatic Diseases, 2016
- Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS studyJournal of the American Academy of Dermatology, 2015
- Safety and Efficacy of Adalimumab for Moderate to Severe Crohn's Disease in ChildrenGastroenterology, 2012
- Induction and Maintenance Infliximab Therapy for the Treatment of Moderate-to-Severe Crohn’s Disease in ChildrenGastroenterology, 2007